Market potential for perfluorcarbon based formulations for use in pressurized metered dosed inhalers for pulmonary drug delivery
Abstract
This effort will help commercialize a novel formulation of inhaled ambrisentan, an endothelin receptor A antagonist, to treat hypoxic pulmonary vasoconstriction, a key pathology of high altitude-induced performance loss. The formulation has shown consistent efficacy in pre-clinical models and is covered by a provisional patent. The team consist of Dr. David Irwin at UC Denver and Dr. Thies Schroeder at University of Mainz, Germany, who cooperate on developing new treatments against high altitude pathologies since 2010, sponsored by the Department of Defense. The inventors are currently under contract with the US Office of Naval Research. Primary prospective customers for the product will be US military personnel that operate at high terrestrial altitude while secondary customers include recreational mountaineers, skiers, and business travelers to high altitude. This formulation may also prove superior to the standard-of-care oral treatment of idiopathic or acquired pulmonary arterial hypertension (PAH). Finally, our novel fluorocarbon-based emulsification technology may be used to deliver other water-soluble drugs that requires fast onset, such as anti-shock or anaphylactic treatment, pain medication, or diabetes drugs.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Oct 17, 2018
- Source ID
- W911NF1710585
Entities
People
- David Irwin
Organizations
- Anschutz Medical Campus
- Army Contracting Command
- Office of the Secretary of Defense